Loading...
Market
Will the merged entity of Recursion and Exscientia announce a new partnership with a large pharmaceutical company by June 30, 2025?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
Official announcements from the merged entity or financial news sources like Bloomberg or Reuters
Story
Recursion and Exscientia Announce $688 Million All-Stock Merger
Aug 8, 2024, 12:52 PM
Recursion Pharmaceuticals and Exscientia have announced a definitive agreement to merge, creating a global leader in AI-driven drug discovery. The merger, valued at $688 million, will be an all-stock deal. This strategic move combines Recursion's high throughput target biology and supercomputing capabilities with Exscientia's generative AI drug design and chemistry automation. The merger aims to accelerate drug discovery, delivering better treatments to patients faster and at lower costs. The combined entity will also gain access to partnerships with large pharmaceutical companies like Sanofi and Merck KGaA.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Increase by more than 5% • 25%
Increase by 1-5% • 25%
No significant change • 25%
Decrease • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
More than 3 new drugs • 25%
2-3 new drugs • 25%
1 new drug • 25%
No new drugs • 25%
Increase by more than 20% • 25%
Increase by 10-20% • 25%
Increase by less than 10% • 25%
No increase or decrease • 25%
Partnership with a major pharmaceutical company • 25%
Acquisition by a major pharmaceutical company • 25%
Partnership with a tech company • 25%
No partnership or acquisition • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Start of Phase 3 trial • 33%
FDA approval • 33%
Partnership announcement • 33%